Literature DB >> 16191800

Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy.

O M Durrani1, T Q Reuser, P I Murray.   

Abstract

We describe a patient with sight threatening thyroid associated ophthalmopathy (TAO) who was successfully treated with infliximab, an anti-tumour necrosis factor (TNF)-a antibody.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16191800     DOI： 10.1080/01676830590912562

Source DB:  PubMed          Journal:  Orbit        ISSN： 0167-6830


  32 in total

Review 1.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Biologic agents in the management of inflammatory eye diseases.

Authors:  Kira Michalova; Lyndell Lim
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

Review 3.  Cytokines, Graves' disease, and thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Nicole Khadavi; Terry J Smith
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

4.  Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.

Authors:  Rina Bhatt; Christine C Nelson; Raymond S Douglas
Journal:  Saudi J Ophthalmol       Date:  2010-11-11

5.  Thyroid associated orbitopathy: Understanding pathophysiology.

Authors:  Imtiaz A Chaudhry
Journal:  Saudi J Ophthalmol       Date:  2010-11-11

Review 6.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

7.  Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.

Authors:  Eric B Suhler; Lyndell L Lim; Robert M Beardsley; Tracy R Giles; Sirichai Pasadhika; Shelly T Lee; Alexandre de Saint Sardos; Nicholas J Butler; Justine R Smith; James T Rosenbaum
Journal:  JAMA Ophthalmol       Date:  2014-05       Impact factor: 7.389

Review 8.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 9.  The pathophysiology of thyroid eye disease: implications for immunotherapy.

Authors:  Raymond S Douglas; Shivani Gupta
Journal:  Curr Opin Ophthalmol       Date:  2011-09       Impact factor: 3.761

10.  Update on the medical treatment of Graves' ophthalmopathy.

Authors:  Gregory J Griepentrog; James A Garrity
Journal:  Int J Gen Med       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.